BG

BGM Group Ltd.

BGMHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$37.9M
+51.1% YoY
Net Income
-$19.9M
-1282.1% YoY
EBITDA
-$11.0M
-1348.6% YoY
Free Cash Flow
$11.2M

Scan Results

Daily timeframe
2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 20▼ MACD Negative CrossoverHistogram -0.0328, negative momentum
Oct 14▲ Above MA150+0.5% from MA150, price crossed above
▼ RSI OverboughtRSI 76.5, above 70, stock may be overbought
About BGM Group Ltd.

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. With a market capitalization of $104.8M, it sits in micro-cap territory. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.

Where BGM stands vs its 150-day and 200-day moving averages

As of the October 20, 2026 close, BGM finished 9.21% below its 150-day moving average ($9.88) and 62.42% below its 200-day moving average ($23.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is BGM overbought or oversold?

At the October 20, 2026 close, BGM's RSI(14) was 60.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$104.8M
EPS$-4.80
52W Change-97.2%
Dividend Yield0.00%
ROE-7.4%
Analysis

With $11.5M in cash and $1.2M in debt, BGM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $11.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -7.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $64.9M (2022) to $37.9M (2025), a 42% decline worth watching.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing BGM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms